Dr. Roger Willette Cv 6w1634

Curriculum Vitae Roger C. Willette, M.D. Professional Address:

President/Physician Owner Advanced Clinical Research Center of Houston 1051 Pineloch Drive, Suite 600 Houston, Texas 77062

Telephone: Fax: Email:

(832) 284-4343 (832) 284-4342 [email protected]

Current Position

Principal Investigator/Owner

Licensure:

Medical License, State of Texas G6771

Board Certifications:

Internal Medicine Certification # 108784

Education:

1983-1986

Internal Medicine Internship and Residency Program Baylor College of Medicine d Residency Training Program, Houston, TX, USA.

1980-1983

Doctor of Medicine Baylor College of Medicine

1978-1980

University of Texas at Austin Austin, Texas

Professional Experience:

1996 – Present

Private Practice – Internal Medicine Roger C. Willette, M.D., P.A. Webster/Houston, Texas Pineloch Infusion Center Roger C. Willette, M.D., P.A Pineloch Wound Care Clinic Roger C. Willette, M.D., P.A.

2010 – Present

Reading Physician for Surgical Neuromonitoring – NDX Technologies

Sept. 2011 – Present

Medical Director, Houston Office of American Institute of Gastric Banding

Curriculum Vitae – Continued Roger C. Willette, M.D. Page Two Professional Experience – Continued: 2007 – Present

Coastal Diagnostic Services Houston, Texas

2007 – 2012

Principal Investigator Centex Research, Inc. Houston, Texas

2010 – Present

Bay Area Medical Weight Loss Center Houston, Texas

Mar 2000-2002

Medical Director Wound Care Program Specialty Hospital, Clear Lake, Webster, Texas

Feb 1996 – 2000

Medical Director Columbia Clear Lake Center for Wound Care and Hyperbaric Medicine Webster, Texas

1993 – 1995

Hospice Team Physician Denson Community Hospice League City, Texas

1994 – 1995

Chief of Medicine Columbia Clear Lake Medical Center Webster, Texas

1989 – 1996

Private Practice of Internal Medicine PRW Medical Consultants Webster, Texas

1988 – 1989

Private Practice of Internal Medicine Advanced Health Center Houston, Texas

1986 -1988

Clinical Instructor of Medicine, Baylor College of Medicine Medical Director Ward 206 Houston Veterans istration Medical Ctr. Houston, Texas

Curriculum Vitae – Continued Roger C. Willette, M.D. Page Three Clinical Investigator Training:ICH Good Clinical Practice for Clinical Trial Sites March 2012 Clinical Research Experience: 2008 – 2009

A Randomized, Double-Blind, Placebo-And-Active Controlled, Parallel Arm, Multicenter Study in Subjects with Third Stage t Disease to Compare the Frequency of Constipation Symptoms in Subjects Treated With Study Drug IR and Oxycodone IR Using a Bowel Function Patient Dairy (the “Study”). Johnson & Johnson, Protocol R33133PA13020

2009 – 2011

A Phase ll, Randomized, Double-Blind, Multidose, Active-And-Placebo Controlled, Multicenter, Parallel Group Study of the Analgesic Effects of Study Drug in Adult Subjects with Chronic Low Back Pain Pfizer Protocol A4091012.

2010 – 2011

An Open-Label, Multicenter, Long Term Study of the Safety of Study Drug In Patients with Chronic Low Back Pain. Pfizer Protocol A4091039.

2010 – 2011

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group, Proof of Concept Study of the Analgesic Effects of Study Drug in Adult Patients with Diabetic Peripheral Neuropathy. Pfizer Protocol A4061031.

2010 – 2011

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study Evaluating the Efficacy and Safety of Study Drug for the Treatment of Moderate to Severe Pain and Other Symptoms Associated with Interstitial Cystitis ( Bladder Pain Syndrome ). Pfizer Protocol A4091035.

2010 – Present

A Multicenter, Randomized, Double-Blind Study of the Co-istration of Study Drug in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control. Protocol #MK 0431, 102

2010 – Present

A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial to Evaluate the Efficacy and Safety of Study Drug, Flexible Dose Regimen in Vulnerable Elderly Patients with Symptoms of Overactive Bladder. Pfizer Protocol A0221049.

Curriculum Vitae – Continued Roger C. Willette, M.D. Page Four

2010 – Present

A Phase 3, Randomized, Double-Blind Evaluation of the Safety and Efficacy of Study Drug in Subjects with Acute Coronary Syndrome. Protocol # CV185068.

2010 – Present

A Phase 2b, Repeat Dosing Clinical Trial of Study Drug in Subjects with Moderate to Severe Diabetic Neuropathy. Protocol #SB-509-0901.

2010 – Present

A Phase 3, Multicenter, Randomized, Open-Label Clinical Trial Comparing the Efficacy and Safety of a Sitagliptin-Based Treatment Paradigm to a LiraglutideBased Treatment Paradigm in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Monotherapy. Protocol #MD-0431.